No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Vitrafy Life Sciences Says US Army Institute Completes Phase One Study of Its Cryopreservation Technology
Vitrafy Life Sciences Ltd: USAISR successful Phase 1 Blood Platelet study
Vitrafy Life Sciences Ltd. Announces Quotation of New Securities on ASX
Vitrafy Life Sciences Price Target Cut 16% to A$1.99/Share by Bell Potter
Vitrafy Life Sciences Ltd. Unveils Half-Year FY2025 Financial Results
Vitrafy Life Sciences Ltd: FY25 Half Year Results Presentation